The Dopamine β-hydroxylase Inhibitor, Nepicastat, Reduces Different Alcohol-related Behaviors in Rats
Overview
Authors
Affiliations
Background: Recent experimental data indicate that treatment with the selective dopamine β-hydroxylase inhibitor, nepicastat, suppressed different reward-related behaviors, including self-administration of chocolate and reinstatement of cocaine and chocolate seeking, in rats. This study was designed to extend to different alcohol-related behaviors the investigation on the "anti-addictive" properties of nepicastat.
Methods: Sardinian alcohol-preferring (sP) rats, selectively bred for excessive alcohol consumption, were exposed to different procedures of alcohol drinking and self-administration.
Results: Repeated treatment with nepicastat (0, 25, 50, and 100 mg/kg, intraperitoneally [i.p.], once daily for 10 consecutive days) produced a stable and dose-related reduction in daily alcohol intake in sP rats exposed to the homecage 2-bottle "alcohol (10% v/v) versus water" choice regimen with unlimited access. Acute treatment with nepicastat (0, 25, 50, and 100 mg/kg, i.p.) completely suppressed the "alcohol deprivation effect" (i.e., the temporary increase in alcohol intake occurring after a period of abstinence; model of alcohol relapse episodes) in sP rats exposed to the 2-bottle choice regimen. Acute treatment with nepicastat (0, 25, 50, and 100 mg/kg, i.p.) dose dependently and selectively reduced oral alcohol self-administration in sP rats trained to lever respond for alcohol (15% v/v) on a fixed ratio 4 schedule of reinforcement. Finally, combination of nepicastat (0, 50, and 100 mg/kg, i.p.) and alcohol (2 g/kg, intragastrically) did not alter spontaneous locomotor activity in sP rats.
Conclusions: Together, these data extend to alcohol the capacity of nepicastat to suppress different behaviors motivated by natural stimuli and drugs of abuse.
Vena A, Zandy S, Cofresi R, Gonzales R Pharmacol Ther. 2020; 212:107573.
PMID: 32437827 PMC: 7580704. DOI: 10.1016/j.pharmthera.2020.107573.
Lustberg D, Iannitelli A, Tillage R, Pruitt M, Liles L, Weinshenker D Psychopharmacology (Berl). 2020; 237(7):1973-1987.
PMID: 32313981 PMC: 7961804. DOI: 10.1007/s00213-020-05512-0.
Di Ciano P, Manvich D, Pushparaj A, Gappasov A, Hess E, Weinshenker D Psychopharmacology (Berl). 2017; 235(1):23-35.
PMID: 29085979 PMC: 5750121. DOI: 10.1007/s00213-017-4744-0.
Devoto P, Flore G, Saba P, Frau R, Gessa G Brain Behav. 2015; 5(10):e00393.
PMID: 26516613 PMC: 4614051. DOI: 10.1002/brb3.393.
Rasmussen D, Kincaid C, Froehlich J Alcohol Clin Exp Res. 2015; 39(9):1832-41.
PMID: 26260061 PMC: 4558320. DOI: 10.1111/acer.12828.